Noile-Immune Biotech Inc.

Equities

4893

JP3759560000

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-16 am EDT			5-day change	1st Jan Change
146 ^JPY	-2.67%		-5.81%	-31.13%

2023	Certain Shares of Noile-Immune Biotech Inc. are subject to a Lock-Up Agreement Ending on 24-DEC-2023.	CI
2023	Jefferies Adjusts Noile-Immune Biotech's Price Target to 440 Yen From 800 Yen, Keeps at Buy	MT

Noile-Immune Biotech Inc. has filed an IPO.

May 25, 2023 at 12:00 am EDT

Noile-Immune Biotech Inc. has filed an IPO.

Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,539,800

Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,083,200

Transaction Features: Regulation S; Rule 144A; Sponsor Backed Offering

Latest news about Noile-Immune Biotech Inc.

Certain Shares of Noile-Immune Biotech Inc. are subject to a Lock-Up Agreement Ending on 24-DEC-2023.	Dec. 23	CI
Jefferies Adjusts Noile-Immune Biotech's Price Target to 440 Yen From 800 Yen, Keeps at Buy	Dec. 19	MT
Japanese Shares Hit 33,000 Mark Again as Yen Slips, BoJ Holds Rates Steady	Dec. 19	MT
Noile-Immune Biotech to Seek New Partnerships After Termination of Takeda License Deal; Shares Surge 23%	Dec. 19	MT
Noile-Immune Biotech Regains Rights to Solid Tumor Drug Candidates as Takeda Terminates License Deal	Dec. 17	MT
Noile-Immune Biotech, Inc. Announces on the Termination of License Agreement for NIB102 and NIB103	Dec. 15	CI
Noile-Immune Biotech Inc. has completed an IPO in the amount of ¥2.68102 billion.	23-06-28	CI
Noile-Immune Biotech Inc. has filed an IPO.	23-05-25	CI

Chart Noile-Immune Biotech Inc.

Duration

Period

More charts

Company Profile

Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

150 JPY

Average target price

440 JPY

Spread / Average Target

+193.33%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NOILE-IMMUNE BIOTECH INC.	-31.13%	41.95M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
ARGENX SE	+1.08%	22.27B
BIONTECH SE	-12.64%	22.22B
GENMAB A/S	-5.52%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.77%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B

Bio Therapeutic Drugs